Advertisement

Search Results

Advertisement



Your search for it matches 15595 pages

Showing 4401 - 4450


head and neck cancer

Pralsetinib for RET-Altered Thyroid Cancers

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 1, 2020, pralsetinib (Gavreto) was granted...

breast cancer

CTC Enumeration Predicts Survival Early in Treatment of Metastatic Breast Cancer

The number of circulating tumor cells (CTCs) assessed at baseline and at about 1 month after cancer-directed treatment was strongly associated with overall survival in patients with metastatic breast cancer, according to a large retrospective pooled analysis reported at the 2020 San Antonio Breast...

Edith Mitchell, MD, Elected to Fellowship in the Royal College of Physicians of London

Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center–Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London (RCP). The RCP was founded in 1518 by a Royal Charter from King Henry VIII. RCP...

Expert Point of View: Stephanie Lee, MD, MPH

ASH President Stephanie Lee, MD, MPH, Associate Director of the Clinical Research Division of Fred Hutchinson Cancer Research Center and Professor at the University of Washington, Seattle, congratulated the investigators on this extensive effort to collect real-world data to inform clinical...

hematologic malignancies
covid-19

ASH Registry: Treasure Trove of Data on COVID-19 and Hematologic Malignancies

The ASH Research Collaborative COVID-19 Registry for Hematology provides up-to-date information on outcomes and the course of illness for a group of patients with hematologic malignancies and COVID-19.1 In general, registry data showed that hematologic malignancies increase the risk of severity of...

ASH Announces Donation of Next-Generation Sequencing Equipment to Countries in the International Consortium

The American Society of Hematology (ASH) recently announced the donation of next-generation sequencing equipment to six reference laboratories in five countries in Latin America. These countries constitute the International Consortium on Acute Leukemia (ICAL), a clinical network supported by the...

Expert Point of View: Jacob Soumerai, MD

“CAPTIVATE is a very important study,” stated Jacob Soumerai, MD, Associate Professor at Harvard Medical School and Massachusetts General Hospital Cancer Center. “The take-home point is that this [ibrutinib plus venetoclax] is highly effective therapy and achieves a high rate of undetectable...

leukemia

Fixed-Duration First-Line Ibrutinib Plus Venetoclax Yields Treatment-Free Remission in Some Patients With CLL

The randomized phase II CAPTIVATE trial showed that a fixed-duration treatment approach with 12 cycles of ibrutinib and venetoclax as first-line therapy for chronic lymphocytic leukemia (CLL) achieved a 30-month progression-free survival of more than 95% in patients with undetectable minimal...

colorectal cancer

My Life of Service to Other Cancer Survivors

Six months before my diagnosis of metastatic colorectal cancer, in 2016, at age 38, I told my mom, “I feel like I’m dying.” Even though more than 10 specialists I had seen over the previous 8 years for unexplained bouts of abdominal pain and bloating, fatigue, and constipation kept assuring me that ...

supportive care
hematologic malignancies

Ruxolitinib Improves Outcomes in Patients With Steroid-Refractory or Steroid-Dependent Graft-vs-Host Disease

Ruxolitinib was superior to best available therapy in achieving efficacy as determined by best overall response and duration of response, with acceptable safety in adolescents and adults with steroid-dependent or steroid-refractory chronic graft-vs-host disease effects. These findings were shown in ...

Cancer Survivor Offers Roadmap for Managing the Turmoil of Diagnosis and Treatment

Although the field of psychosocial oncology had its roots in the 1970s, it wasn’t until 2007 that the Institute of Medicine acted on the growing data describing the impact of emotional well-being and physical recovery on quality of life, establishing guideline standards requiring that the...

Adamantinoma of the Mandible

The text and photographs here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Radium Era 1916–1945 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photographs appear courtesy of Stanley B. Burns, MD, and The Burns...

Tabaré Vázquez, Former President of Uruguay, Oncologist, and Human Rights Activist, Dies at 80

In 2006, President of Uruguay Dr. Tabaré Vázquez, a radiation oncologist by profession, enacted comprehensive antismoking legislation, eventually leading Uruguay to become the first country in Latin America to prohibit smoking in enclosed public spaces. His bold action drew the ire of international ...

issues in oncology

Challenges Related to Informed Consent and Information-Sharing for Minors With Cancer

Here we discuss a complex and often emotionally wrenching challenge related to informed consent in the provision of pediatric cancer care. For example, what legal and ethical claims do young patients have to information about their cancer diagnosis and treatment recommendations? What are the...

bladder cancer
genomics/genetics

Germline-Somatic Interactions in Advanced Urothelial Cancer and Their Role in Disease Progression

In a study reported in Nature Communications, Bishoy M. Faltas, MD, of the Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, and colleagues identified common germline-somatic variant interactions in advanced urothelial cancer, with these...

covid-19

Life and Death Under COVID-19

Victoria was a 79-year-old woman living alone in a London suburb. Having no children of her own, she visited us regularly here in the United States. She was one of three sisters and my sister-in-law. I knew her for more than 50 years, and she always reminded me of Audrey Hepburn, both in looks and ...

solid tumors
immunotherapy

Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow

On November 25, 2020, naxita­mab-gqgk (Danyelza) was granted accelerated approval for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone...

lymphoma
immunotherapy

Initial Therapy for Asymptomatic Follicular Lymphoma: Start With Watch and Wait or Rituximab

For patients with indolent follicular lymphoma, generally take a conservative approach to treatment unless the patient is symptomatic, advised John P. Leonard, MD, Executive Vice-Chair of Weill Department of Medicine at Weill-Cornell Medicine/NewYork-Presbyterian, New York.1 “Prognostic scores are...

breast cancer

RxPONDER: Many Postmenopausal Patients With Node-Positive Breast Cancer Can Avoid Chemotherapy

Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage hormone receptor–positive, HER2-negative breast cancer and node-positive disease.1 The data showed that many postmenopausal women can skip adjuvant chemotherapy, based on ...

2020 FDA Approvals of Drugs for Cancer Treatment

Over the past year (January to December 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in oncology and hematology. A brief review of new approvals appears here. For complete prescribing information for ...

multiple myeloma
genomics/genetics

Identifying Multiple Myeloma Prognostic Subgroups With Distinct Genetic and Clinical Features

Multiple myeloma is the second most common blood cancer, after non-Hodgkin lymphoma, diagnosed in the United States. In 2020, it is estimated that about 32,270 people will be diagnosed with the cancer, and despite advances in more effective treatments, nearly 13,000 will die of the disease.1...

hematologic malignancies

Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome, Study Reports

Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...

Daughter of a Dance Band Leader Becomes Nationally Regarded Expert in Disparities of Cancer Care

Electra D. Paskett, PhD, was born in New York City, the daughter of a Greek immigrant who led a notable dance band. As a young child, Dr. Paskett frequented her parents’ rehearsal and dance studio, which was situated above a bustling Woolworth’s Five-and-Dime store. One of the studio’s famous...

prostate cancer

FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer

Today, the U.S. Food and Drug Administration (FDA) approved relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer.  “Today’s approval marks the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require...

issues in oncology

Overcoming the Challenges of Addressing Race, Culture, and Structural Inequality in Medical Education

In 2017, a workgroup task force, made up of medical students and faculty at George Washington University, Texas Christian University, and the University of North Texas Health Science Center, conducted a literature review to identify best practices for teaching and learning about race and culture in ...

gastroesophageal cancer
issues in oncology

Study Finds Incidence of Young-Onset Esophageal Adenocarcinoma Is Rapidly Increasing

A new study published by Codipilly et al in Cancer Epidemiology, Biomarkers & Prevention investigated the trends in incidence, stage at presentation, and survival outcomes of young-onset esophageal adenocarcinoma—defined as patients aged 50 and younger at diagnosis—over the past 4 decades....

Strict Adherence to Algorithm Required

A prospective cohort study found sentinel lymph node biopsy had a 96% sensitivity rate and a 99% negative predictive value for detecting nodal metastasis among patients with clinical stage I low-grade and high-grade endometrial cancer.1 “Our study suggests that [sentinel lymph node biopsy] has...

gynecologic cancers

Study Shows Sentinel Lymph Node Biopsy to Be 'Viable Option' for Surgical Staging of Endometrial Cancer

Sentinel lymph node biopsy “had similar diagnostic accuracy and prognostic ability as lymphadenectomy in patients with high-grade endometrial cancer at greatest risk for nodal metastases,” according to the SENTOR trial, a prospective cohort study of 156 patients with clinical stage I disease. Using ...

leukemia

Study Finds Survival Disparities and Mutational Differences for Black Patients Younger Than 60 With AML

It has been well documented that, collectively, Black individuals have the highest death rates and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also have the highest cancer incidence.1 Although the causes of these inequities are complex and include...

breast cancer

Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with...

palliative care
symptom management

Reducing the Risk of Lymphedema in Patients With Cancer

Although the exact incidence of treatment-related lymphedema among cancer survivors is unknown—most likely due to its prolonged latency period—it can be a lifelong chronic side effect that negatively impacts survivors’ quality of life. Although the condition is often linked to treatment for breast...

breast cancer
geriatric oncology

Addition of Chemotherapy to Local Therapy in Women Aged 70 or Older With Triple-Negative Breast Cancer

In a National Cancer Database analysis reported in The Lancet Oncology, Crozier et al found that receipt of neoadjuvant or adjuvant chemotherapy was associated with improved overall survival among women aged 70 or older undergoing surgery for stage I to III triple-negative breast cancer. Study...

bladder cancer
genomics/genetics

Spectrum of Germline-Somatic Interactions in Advanced Urothelial Cancer

In a study reported in Nature Communications, Vosoughi et al identified common germline-somatic variant interactions in advanced urothelial cancer, with these interactions appearing to play a central role in disease progression. As stated by the investigators, “The prevalence and the biologic...

Eric P. Winer, MD, FASCO, Elected ASCO President for 2022–2023 Term

ASCO has elected Eric P. Winer, MD, FASCO, a longtime member and volunteer, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Five new members were also elected to the ASCO Board of Directors and the...

covid-19

FDA Authorizes Antigen Test as First Over-the-Counter, Fully At-Home Diagnostic Test for COVID-19

On December 15, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first over-the-counter, fully at-home diagnostic test for COVID-19. The Ellume COVID-19 Home Test is a rapid, lateral-flow antigen test, a type of test that runs a liquid sample along a...

issues in oncology

Trends in AYA Cancer Incidence in the United States Over 4 Decades

Cancer cases in adolescents and young adults (AYAs) have risen by 30% during the past 4 decades, with rates of kidney cancer increasing at the greatest rate, according to findings published by Scott et al in JAMA Network Open. The team said further research into screening, diagnosis, and treatment...

lung cancer
immunotherapy

ESMO Immuno-Oncology 2020: Does Pleural Effusion Affect Survival in Patients Treated With Immunotherapy for NSCLC?

Patients with non–small cell lung cancer (NSCLC) who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immune checkpoint inhibitors, according to findings presented by Epaillard et al at the European Society for Medical Oncology...

breast cancer

Cost-Effectiveness of Neoadjuvant/Adjuvant Treatment Strategies for HER2-Positive Breast Cancer

In a study reported in JAMA Network Open, Kunst et al compared five neoadjuvant-adjuvant treatment strategies for patients with HER2-positive breast cancer and identified one that was associated with both improved outcomes and cost savings. The researchers found that a strategy of neoadjuvant...

breast cancer

SABCS 2020: CTC Enumeration May Be Predictive of Survival During Treatment for Metastatic Breast Cancer

The number of circulating tumor cells (CTCs) assessed at baseline and about 1 month after cancer-directed treatment was associated with overall survival in patients with metastatic breast cancer, according to findings from a large retrospective pooled analysis reported by Wolfgang Janni, MD, PhD,...

covid-19

FDA Issues Emergency Use Authorization for First COVID-19 Vaccine

On December 11, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for a vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in individuals aged 16 and older. The EUA allows the Pfizer-BioNTech COVID-19 vaccine to be distributed in the United...

breast cancer

SABCS 2020: RxPONDER Study Shows Postmenopausal Patients With Node-Positive Breast Cancer May Be Able to Avoid Chemotherapy

Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage, hormone receptor (HR)-positive, node-positive breast cancer. Based on the findings, many postmenopausal women may be able to safely skip adjuvant chemotherapy. However,...

lymphoma
immunotherapy

ASH 2020: Phase II ZUMA-12 Study Investigates Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma

The phase II ZUMA-12 trial found that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is a safe and effective therapy for patients with high-risk large B-cell lymphoma. These results were presented by Sattva S. Neelapu, MD, and colleagues at the 2020 ...

breast cancer

Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival

In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is associated with a decrease in survival, regardless of the receptor status. Patients with breast cancer who received neoadjuvant...

SITC Announces Creation of Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund

The Society for Immunotherapy of Cancer (SITC) has announced the creation of the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund. Established in honor of Dr. Rosenberg, this fund recognizes his many contributions to the field by supporting investigators who are emerging leaders in...

2020 E. Donnall Thomas Lecture and Prize Awarded to Toshio Suda, MD, PhD

The American Society of Hematology (ASH) presented the 2020 E. Donnall Thomas Lecture and Prize to Toshio Suda, MD, PhD, of the National University of Singapore and Japan’s International Research Center for Medical Sciences, Kumamoto University, for his outstanding contributions to the field of...

Shilpi Gupta, MD, Joins Atlantic Health System Cancer Care’s Comprehensive Breast Health Program

Atlantic Health System Cancer Care recently announced that fellowship-trained medical oncologist Shilpi Gupta, MD, has joined Morristown Medical Center’s comprehensive breast health program, where her focus is breast oncology and research. Dr. Gupta is on staff at Atlantic Hematology Oncology at...

issues in oncology

The Problem of ­Heterogeneity Within Stage

The more senior of this duo grew up with prognostication by disease stage and was taught that all stage IV cancers behaved the same. In the past 3 decades, we have become much more cognizant of the heterogeneity in outcome within stage. Individual Kaplan-Meier plots by stage separate well but hide...

New ASCO Series for Early-Career Cancer Providers on Impacts of Social Determinants of Health

As part of its ongoing commitment to addressing inequities in cancer care and research, ASCO has launched a new educational series focused on the role of social determinants of health in cancer care and cancer outcomes. The free series, which began October 21, is aimed at educating oncology...

Career Development Award Winner Dr. Aparna Parikh on the Emerging Importance of Liquid Biopsies for GI Cancers

Systematic liquid biopsies are transforming treatment approaches for patients with gastrointestinal (GI) cancers. Many GI tumors are detected late, which ultimately reduces 5-year overall survival rates. Liquid biopsies may become increasingly important both in the early detection and treatment...

ASCO Announces Julie R. Gralow, MD, FACP, FASCO, as New Chief Medical Officer

Julie R. Gralow, MD, FACP, FASCO, Professor of Medical Oncology and Director of Breast Medical Oncology at the University of Washington, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance, has been named the next Chief Medical Officer of ASCO. Dr. Gralow will succeed...

Advertisement

Advertisement




Advertisement